RELATIVITY-1093

1L NSQ PD-L1 ≥1% NSCLC



A Clinical Study in Non-small Cell Lung Cancer (NSCLC)

For patients with non-squamous recurrent or stage IV NSCLC who have not received prior treatments for advanced NSCLC.

ClinicalTrials.gov Number: NCT06561386

BMS-NSCLCTrials.com/RELA-1093

About the CA224-1093 Clinical Study

What is the RELATIVITY1093 Clinical Study?

RELATIVITY1093 is a Phase 3 clinical study for people who have stage IV or recurrent non-squamous NSCLC. This means the primary tumor in the lung has spread to other parts of the body.

Participants will be randomly assigned to receive either the study drug (nivolumab + relatlimab) in combination with chemotherapy or pembrolizumab (Keytruda®) in combination with chemotherapy.

What is Relatlimab?

Relatlimab is an investigational immunotherapy that targets a protein called LAG-3, which plays a role in preventing the immune system's ability to fight cancer. By blocking LAG-3, relatlimab aims to enhance the body's immune response, potentially improving cancer treatment outcomes.

It is being studied in combination with other therapies to treat various types of cancer.

You may be eligible to join the RELATIVITY1093 study if you are at least 18 years of age and:

- You were diagnosed with non-squamous advanced NSCLC after tumor sample.
- You have not received any prior treatments for your advanced non-squamous NSCLC.
- The non-squamous NSCLC has recurred or has spread to other parts of the body.
- You will need to have test results from other assays to be eligible for the trial, including tests results for specific mutations, blood-based laboratory test results and assessment of your physical condition.

Clinical studies have strict rules to protect participants and ensure reliable results. Your doctor can help you determine if you're eligible and if the study is right for you by reviewing your health history and the requirements.

For Physicians

To discuss a potential patient referral, please contact your nearest Principal Investigator or site staff to learn more

ClinicalTrials.gov identifier:

NCT06561386